TNGX (STOCKS)
Tango Therapeutics, Inc.
$25.650000
+0.070000 (+0.27%)
Prev close: $25.580000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Malte Peters
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $4,328.22M
- Employees
- 155
- P/E (TTM)
- -30.54
- P/B (TTM)
- 4.20
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $53.81M |
| Nonoperating Income/Loss | $12.56M |
| Operating Expenses | $190.16M |
| Research and Development | $133.65M |
| Other Operating Expenses | $56.51M |
| Operating Income/Loss | -$136.35M |
| Income/Loss From Continuing Operations After Tax | -$123.72M |
| Income/Loss From Continuing Operations Before Tax | -$123.78M |
| Income Tax Expense/Benefit | -$63.00K |
| Interest Income/Expense After Provision For Losses | $8.68M |
| Interest Income/Expense Operating, Net | $8.68M |
| Net Income/Loss | -$123.72M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$123.72M |
| Net Income/Loss Available To Common Stockholders, Basic | -$123.72M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Provision For Loan, Lease, And Other Losses | $0.00 |
| Basic Earnings Per Share | -$0.85 |
| Diluted Earnings Per Share | -$0.86 |
| Basic Average Shares | 409,823,090 |
| Diluted Average Shares | 416,638,819 |
| Assets | $1.07B |
| Current Assets | $1.03B |
| Cash | $1.00B |
| Other Current Assets | $31.67M |
| Noncurrent Assets | $42.21M |
| Fixed Assets | $6.09M |
| Other Non-current Assets | $36.12M |
| Liabilities | $49.35M |
| Current Liabilities | $20.30M |
| Accounts Payable | $1.81M |
| Wages | $5.70M |
| Other Current Liabilities | $12.79M |
| Noncurrent Liabilities | $29.05M |
| Equity | $1.02B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $1.02B |
| Temporary Equity | $0.00 |
| Temporary Equity Attributable To Parent | $0.00 |
| Liabilities And Equity | $1.07B |
| Net Cash Flow From Operating Activities | -$143.90M |
| Net Cash Flow From Operating Activities, Continuing | -$143.90M |
| Net Cash Flow From Investing Activities | -$524.58M |
| Net Cash Flow From Investing Activities, Continuing | -$524.58M |
| Net Cash Flow From Financing Activities | $974.33M |
| Net Cash Flow From Financing Activities, Continuing | $974.33M |
| Net Cash Flow | $305.86M |
| Net Cash Flow, Continuing | $305.86M |
| Comprehensive Income/Loss | -$124.11M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$124.45M |
| Other Comprehensive Income/Loss | -$39.85M |